Association Study between Promoter Polymorphisms of ADAM17 and Progression of Sepsis

Cellular Physiology and Biochemistry

Volumn 39, Issue 4, 2016, Pages 1247-1261

  Shao, Yiming ^a   He, Junbing ^a   Chen, Feng ^a   Cai, Yujie ^a   Zhao, Jianghao ^a   Lin, Yao ^a   Yin, Zihan ^a   Tao, Hua ^a   Shao, Xin ^a   Huang, Pengru ^a   Yin, Mingkang ^a   Zhang, Wenying ^a   Liu, Zhou ^a   Cui, Lili ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

ADAM17; CX3CL1; IL 6R; Polymorphism; Pro inflammation cytokines; Sepsis; TNF

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; DNA; FRACTALKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ADAM17 PROTEIN, HUMAN; CX3CL1 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE COURSE; DNA ISOLATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; CASE CONTROL STUDY; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM17 PROTEIN; ADULT; CASE-CONTROL STUDIES; CHEMOKINE CX3CL1; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERLEUKIN-6; SEPSIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84986552361     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447830     Document Type: Article

References (54)

1. Lewis DH, Chan DL, Pinheiro D, Armitage-Chan E, Garden OA: The immunopathology of sepsis: Pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response, and regulatory t cells. J Vet Intern Med 2012; 26: 457-482.
2. Zeng L, Du J, Gu W, Zhang AQ, Wang HY, Wen DL, Qiu L, Yang XT, Sun JH, Zhang M, Hao J, Jiang JX: Rs1800625 in the receptor for advanced glycation end products gene predisposes to sepsis and multiple organ dysfunction syndrome in patients with major trauma. Crit Care 2015; 19: 6.
3. Zhang J, Yang J, Xu X, Liang L, Sun H, Liu G, Zhang L, Su Y: The influence of genetic polymorphisms in tlr4 and tirap, and their expression levels in peripheral blood, on susceptibility to sepsis. Exp Ther Med 2016; 11: 131-139.
4. Beppler J, Koehler-Santos P, Pasqualim G, Matte U, Alho CS, Dias FS, Kowalski TW, Velasco IT, Monteiro RC, Pinheiro da Silva F: Fc gamma receptor iia (cd32a) r131 polymorphism as a marker of genetic susceptibility to sepsis. Inflammation 2016; 39: 518-525.
5. Georgitsi MD, Vitoros V, Panou C, Tsangaris I, Aimoniotou E, Gatselis NK, Chasou E, Kouliatsis G, Leventogiannis K, Velissaris D, Belesiotou E, Dioritou-Aggaliadou O, Giannitsioti E, Netea MG, Giamarellos-Bourboulis EJ, Giannikopoulos G, Alexiou Z, Voloudakis N, Koutsoukou A, Hellenic Sepsis Study G: Individualized significance of the-251 a/t single nucleotide polymorphism of interleukin-8 in severe infections. Eur J Clin Microbiol Infect Dis 2016; 35: 563-570.
6. Lee K, Chang Y, Song K, Park YY, Huh JW, Hong SB, Lim CM, Koh Y: Associations between single nucleotide polymorphisms of high mobility group box 1 protein and clinical outcomes in korean sepsis patients. Yonsei Med 2016; 57: 111-117.
7. Cai M, Wang Z, Zhang J, Zhou H, Jin L, Bai R, Weng Y: Adam17, a target of mir-326, promotes emt-induced cells invasion in lung adenocarcinoma. Cell Physiol Biochem 2015; 36: 1175-1185.
8. Chen B, Huang Z, Zhang Y, Chen Y, Li Z: Microrna-145 suppresses osteosarcoma metastasis via targeting mmp16. Cell Physiol Biochem 2015; 37: 2183-2193.
9. Dreymueller D, Uhlig S, Ludwig A: Adam-family metalloproteinases in lung inflammation: Potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol 2015; 308: L325-343.
10. Edwards DR, Handsley MM, Pennington CJ: The adam metalloproteinases. Mol Aspects Med 2008; 29: 258-289.
11. Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M: The role of adam17 in metabolic inflammation. Atherosclerosis 2013; 228: 12-17.
12. Scheller J, Chalaris A, Garbers C, Rose-John S: Adam17: A molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011; 32: 380-387.
13. Lisi S, D'Amore M, Sisto M: Adam17 at the interface between inflammation and autoimmunity. Immunol Lett 2014; 162: 159-169.
14. Chang MC, Chan CP, Chen YJ, Hsien HC, Chang YC, Yeung SY, Jeng PY, Cheng RH, Hahn LJ, Jeng JH: Areca nut components stimulate adam17, il-1alpha, pge2 and 8-isoprostane production in oral keratinocyte: Role of reactive oxygen species, egf and jak signaling. Oncotarget 2016; 7: 16879-16894.
15. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, O'Toole EA, Martin JE, Lindley K, Vulliamy T, Abrams DJ, MacDonald TT, Harper JI, Kelsell DP: Inflammatory skin and bowel disease linked to adam17 deletion. N Engl J Med 2011; 365: 1502-1508.
16. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Hasler R, Becker C, Neurath MF, Reiss K, Saftig P, Scheller J, Rose-John S: Critical role of the disintegrin metalloprotease adam17 for intestinal inflammation and regeneration in mice. J Exp Med 2010; 207: 1617-1624.
17. Kermarrec N, Selloum S, Plantefeve G, Chosidow D, Paoletti X, Lopez A, Mantz J, Desmonts JM, Gougerot-Pocidalo MA, Chollet-Martin S: Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: Role of tumor necrosis factor-alpha converting enzyme cleavage. Crit Care Med 2005; 33: 1359-1364.
18. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel CP: Cutting edge: Tnf-alpha-converting enzyme (tace/adam17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007; 179: 2686-2689.
19. Long C, Wang Y, Herrera AH, Horiuchi K, Walcheck B: In vivo role of leukocyte adam17 in the inflammatory and host responses during e. Coli-mediated peritonitis. J Leukoc Biol 2010; 87: 1097-1101.
20. Long C, Hosseinkhani MR, Wang Y, Sriramarao P, Walcheck B: Adam17 activation in circulating neutrophils following bacterial challenge impairs their recruitment. J Leukoc Biol 2012; 92: 667-672.
21. Tsuji F, Oki K, Okahara A, Suhara H, Yamanouchi T, Sasano M, Mita S, Horiuchi M: Differential effects between marimastat, a tnf-alpha converting enzyme inhibitor, and anti-tnf-alpha antibody on murine models for sepsis and arthritis. Cytokine 2002; 17: 294-300.
22. Li X, Yan Y, Huang W, Yang Y: The study of the inhibition of the recombinant tace prodomain to endotoxemia in mice. Int J Mol Sci 2009; 10: 5442-5454.
23. Qu D, Wang Y, Esmon NL, Esmon CT: Regulated endothelial protein c receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/adam17. J Thromb Haemost 2007; 5: 395-402.
24. Song D, Ye X, Xu H, Liu SF: Activation of endothelial intrinsic nf-{kappa}b pathway impairs protein c anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009; 114: 2521-2529.
25. Peng Q, Deng Y, Yang X, Leng X, Yang Y, Liu H: Genetic variants of adam17 are implicated in the pathological process of kawasaki disease and secondary coronary artery lesions via the tgf-beta/smad3 signaling pathway. Eur J Pediatr 2016; 175: 705-713.
26. Junyent M, Parnell LD, Lai CQ, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M, An P, Smith CE, Lee YC, Borecki I, Ordovas JM: Adam17i33708a>g polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the genetics of lipid lowering drugs and diet network study. Nutr Metab Cardiovasc Dis 2010; 20: 698-705.
27. Wang M, Li Y, Lu Y, Zuo X, Wang F, Zhang Z, Jia J: The relationship between adam17 promoter polymorphisms and sporadic alzheimer's disease in a northern Chinese han population. J Clin Neurosci 2010; 17: 1276-1279.
28. Li Y, Cui LL, Li QQ, Ma GD, Cai YJ, Chen YY, Gu XF, Zhao B, Li KS: Association between adam17 promoter polymorphisms and ischemic stroke in a Chinese population. J Atheroscler Thromb 2014; 21: 878-893.
29. Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, Rupprecht HJ, Lackner K, Barbaux S, Poirier O, Peiretti F, Nalbone G, Juhan-Vague I, Blankenberg S, Tiret L: Polymorphisms of the tumor necrosis factor-alpha (tnf) and the tnf-alpha converting enzyme (tace/adam17) genes in relation to cardiovascular mortality: The atherogene study. J Mol Med (Berl) 2008; 86: 1153-1161.
30. Holdt LM, Thiery J, Breslow JL, Teupser D: Increased adam17 mrna expression and activity is associated with atherosclerosis resistance in ldl-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 1097-1103.
31. Li Y, Yang C, Ma G, Cui L, Gu X, Chen Y, Zhao B, Wang H, Li K: Analysis of adam17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm. Cell Physiol Biochem 2014; 33: 1426-1438.
32. Zeng L, Zhang AQ, Gu W, Zhou J, Zhang LY, Du DY, Zhang M, Wang HY, Yan J, Yang C, Jiang JX: Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma. Crit Care 2012; 16: R131.
33. Baghel K, Srivastava RN, Chandra A, Goel SK, Agrawal J, Kazmi HR, Raj S: Tnf-alpha, il-6, and il-8 cytokines and their association with tnf-alpha-308 g/a polymorphism and postoperative sepsis. J Gastrointest Surg 2014; 18: 1486-1494.
34. Fakhri D, Djauzi S, Murni TW, Rachmat J, Harahap AR, Rahayuningsih SE, Mansyur M, Santoso A: Genetic polymorphism in postoperative sepsis after open heart surgery in infants. Asian Cardiovasc Thorac Ann 2016; 24: 326-331.
35. Cui L, Gao Y, Xie Y, Wang Y, Cai Y, Shao X, Ma X, Li Y, Ma G, Liu G, Cheng W, Liu Y, Liu T, Pan Q, Tao H, Liu Z, Zhao B, Shao Y, Li K: An adam10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis. Crit Care 2015; 19: 73.
36. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric S: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
37. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 801-810.
38. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Apache ii: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
39. Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, Hattersley AT: Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care 2005; 28: 1751-1756.
40. Dollery CM, Libby P: Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-635.
41. Schwarz J, Schmidt S, Will O, Koudelka T, Kohler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, Schwake M, Rose-John S, Chalaris A: Polo-like kinase 2, a novel adam17 signaling component, regulates tumor necrosis factor alpha ectodomain shedding. J Biol Chem 2014; 289: 3080-3093.
42. DeBerge MP, Ely KH, Cheng GS, Enelow RI: Adam17-mediated processing of tnf-alpha expressed by antiviral effector cd8+ t cells is required for severe t-cell-mediated lung injury. PloS one 2013; 8: e79340.
43. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts MS, Syres G, Venkatesh B, Group AN-SI-ACT: A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187: 743-750.
44. Dusterhoft S, Michalek M, Kordowski F, Oldefest M, Sommer A, Roseler J, Reiss K, Grotzinger J, Lorenzen I: Extracellular juxtamembrane segment of adam17 interacts with membranes and is essential for its shedding activity. Biochemistry 2015; 54: 5791-5801.
45. Schwarz N, Pruessmeyer J, Hess FM, Dreymueller D, Pantaler E, Koelsch A, Windoffer R, Voss M, Sarabi A, Weber C, Sechi AS, Uhlig S, Ludwig A: Requirements for leukocyte transmigration via the transmembrane chemokine cx3cl1. Cell Mol Life Sci 2010; 67: 4233-4248.
46. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW: Tumor necrosis factor-alpha-converting enzyme (adam17) mediates the cleavage and shedding of fractalkine (cx3cl1). J Biol Chem 2001; 276: 37993-38001.
47. Garbers C, Janner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch-Nolte F, Rose-John S, Scheller J: Species specificity of adam10 and adam17 proteins in interleukin-6 (il-6) trans-signaling and novel role of adam10 in inducible il-6 receptor shedding. J Biol Chem 2011; 286: 14804-14811.
48. Dusterhoft S, Hobel K, Oldefest M, Lokau J, Waetzig GH, Chalaris A, Garbers C, Scheller J, Rose-John S, Lorenzen I, Grotzinger J: A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor. J Biol Chem 2014; 289: 16336-16348.
49. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888.
50. Uchikawa S, Yoda M, Tohmonda T, Kanaji A, Matsumoto M, Toyama Y, Horiuchi K: Adam17 regulates il-1 signaling by selectively releasing il-1 receptor type 2 from the cell surface. Cytokine 2015; 71: 238-245..
51. Lisi S, Sisto M, Lofrumento DD, D'Amore M: Sjogren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving tace/nf-kappab. Lab Invest 2012; 92: 615-624.
52. Yan I, Schwarz J, Lucke K, Schumacher N, Schumacher V, Schmidt S, Rabe B, Saftig P, Donners M, Rose-John S, Mittrucker HW, Chalaris A: Adam17 controls il-6 signaling by cleavage of the murine il-6ralpha from the cell surface of leukocytes during inflammatory responses. J Leukoc Biol 2016; 99: 749-760.
53. Tsukerman P, Eisenstein EM, Chavkin M, Schmiedel D, Wong E, Werner M, Yaacov B, Averbuch D, Molho-Pessach V, Stepensky P, Kaynan N, Bar-On Y, Seidel E, Yamin R, Sagi I, Elpeleg O, Mandelboim O: Cytokine secretion and nk cell activity in human adam17 deficiency. Oncotarget 2015; 6: 44151-44160.
54. Zhang Y, Hegen M, Xu J, Keith JC, Jr., Jin G, Du X, Cummons T, Sheppard BJ, Sun L, Zhu Y, Rao VR, Wang Q, Xu W, Cowling R, Nickerson-Nutter CL, Gibbons J, Skotnicki J, Lin LL, Levin J: Characterization of (2r, 3s)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-n, 3-dihydroxybutana-mide, a potent and selective inhibitor of tnf-alpha converting enzyme. Int Immunopharmacol 2004; 4: 1845-1857